MapLight Therapeutics, Inc.

MapLight Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing small-molecule therapies for central nervous system disorders. Its pipeline is built around muscarinic receptor programs, including ML-007C-MA for schizophrenia and Alzheimer's disease psychosis and ML-004 for autism spectrum disorders.

20.01

20.01

— MapLight Therapeutics, Inc.
%
Clinical-stage product candidates0% Drug candidates under preclinical and clinical development for CNS indications.
Discovery platform0% Internal platform used to identify circuit-specific pathways and new indications.
Licensed intellectual property0% In-licensed and acquired technology rights supporting the pipeline.
Collaborative development0% Strategic collaborations and licensing arrangements that may support development.

MapLight does not yet sell commercial products, so its direct customers are not patients or hospitals today...

  • Future patients in CNS indicationsprimary

    Patients with schizophrenia, Alzheimer's disease psychosis, and autism spectrum disorders who would use approved therapies if development succeeds.

  • Pharmaceutical collaboration partnerssecondary

    Potential partners that may fund, license, or co-develop MapLight's programs to reduce development risk and extend reach.

  • Healthcare payors and reimbursement systemssecondary

    Public and private payors that would need to cover any approved therapy, affecting adoption and pricing power.

  • Clinicians and treatment centerssecondary

    Psychiatrists, neurologists, and specialty care providers who would prescribe and administer approved CNS treatments.

MapLight is a U.S.-based company and currently expects commercialization efforts, if any, to begin in the United States...

  • •Headquartered in the United States
  • •Current development and planned initial commercialization focus on the U.S.
  • •Relies on third-party CROs and CMOs that may be located outside the U.S.
  • •No country-level revenue disclosed because the company has no product sales
  • •Geographic risk is mainly regulatory, supply-chain, and macroeconomic exposure

MapLight's strategy is to advance its muscarinic receptor pipeline through clinical development while expanding the...

01
Advance lead programs through clinical and preclinical milestonesshort-term

Clinical progress is the main value driver for a company with no commercial revenue.

02
Broaden the platform into additional indicationsmedium-term

More indications can improve the probability of success and expand the addressable market.

03
Secure external capital and strategic collaborationsshort-term

The company will need substantial additional funding before any product revenue is possible.

04
Build intellectual property and development capabilitymedium-term

Patent protection and development execution are essential to future commercialization value.

MapLight faces the classic risks of a clinical-stage biotech: no product revenue, heavy cash burn, and uncertainty...

critical

Clinical development failure

The company is still testing product candidates and may not demonstrate safety or efficacy.

Scope
ML-007C-MA, ML-004 and future pipeline assets
Materiality
high
high

Financing and dilution risk

The company expects substantial additional capital needs before any product sales.

Scope
Operating runway, equity issuance, collaboration terms
Materiality
high
high

Competitive displacement

Other biotech and pharma companies may reach the market faster or with better therapies.

Scope
Schizophrenia, ADP, and autism spectrum disorder markets
Materiality
high
high

Intellectual property protection

Weak or challenged patents could allow competitors to copy or block commercialization.

Scope
ML-007C-MA, ML-004, and platform technologies
Materiality
high
medium

Third-party manufacturing and CRO dependence

Clinical supply and trial execution rely on external vendors and contractors.

Scope
Preclinical materials, clinical trial supply, outsourced operations
Materiality
medium
Research and development expense estimation
Affects operating loss and comparability across quarters
Equity method investment accounting
Can create non-cash volatility in other income/expense
Stock-based compensation
Inflates operating expenses without immediate cash outflow
Milestone and license obligations
Can affect cash needs and dilution
Going-concern and runway assumptions
Important for liquidity assessment and financing risk

Gain Therapeutics, Inc.

GANX · Pharmaceutical Preparations

Minerva Neurosciences, Inc.

NERV · Pharmaceutical Preparations

Pasithea Therapeutics Corp.

KTTAW · Pharmaceutical Preparations

LB PHARMACEUTICALS INC

LBRX · Pharmaceutical Preparations

Neuphoria Therapeutics Inc.

NEUP · Pharmaceutical Preparations

ANAVEX LIFE SCIENCES CORP.

AVXL · Biological Products, (No Diagnostic Substances)

: 28/04/2026